# Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

> **NCT01082068** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 72 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** XL147 (SAR245408)
- **DRUG:** XL765 (SAR245409)
- **DRUG:** letrozole (Femara)

## Key facts

- **NCT ID:** NCT01082068
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2016-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082068, "Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01082068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*